Status:
UNKNOWN
Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus With Body Mass Index (BMI) < 35
Lead Sponsor:
Weill Medical College of Cornell University
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The aim of this study is to evaluate the effect of Roux-en-y gastric bypass (RYGB) in controlling diabetes in subjects with mild obesity (BMI 26-35). The primary endpoint will be the reduction of HbA1...
Detailed Description
The primary endpoint will be the reduction of HbA1c and secondary endpoints will be multiple associated parameters as listed below. A group of 50 subjects with medically documented T2DM and BMI of 26-...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult males and females who meet the following inclusion criteria will be offered the opportunity to participate in the study:
- Diagnosis of type 2 Diabetes Mellitus (T2DM) confirmed by the following criteria:
- normal or high C-peptide level (\> 0.9 ng/ml) to exclude type 1 Diabetes Mellitus
- positive glucagon test to confirm T2DM
- fasting plasma glucose of 126 mg/dl or more on at least two occasions
- Body mass index (BMI) 26 kg/m2 or greater, and less than 35 kg/m2
- History of T2DM for not longer than 8 years, as long-standing disease beyond 8 years correlates with failure to achieve diabetes resolution after gastric bypass
- No contraindication for surgery or general anesthesia as determined by a multidisciplinary bariatric surgery team (surgeon, anesthesiologist, internist, dietitian, psychologist)
- Between 18 and 65 year of age
- Able to provide informed consent
- If a female with reproductive potential, she has to agree to use a reliable method of birth control for at least one year from the date of surgery
- Exclusion Criteria
- Subjects who meet any of the following exclusion criteria will not be eligible to participate in the study:
- Enrollment in another clinical study, which involves an investigational drug
- Diagnosis of type 1 Diabetes Mellitus or other genetic forms of Diabetes Mellitus
- Significant renal failure of chronic liver disease (except NAFLD)
- Major psychological disorders
- Pregnancy - all female subjects will have serum beta-hCG prior to operation, and must use birth control of their choice to avoid pregnancy during the first year after surgery
- Previous gastric or esophageal surgery
- Immunosuppressive drugs including corticosteroids
- Coagulopathy defined as an INR \> 1.5 or platelet count \< 50,000/µl
- Anemia defined as a Hb \<10.0 g/dl
- Inflammatory bowel diseases or other medical condition that would serve as a contraindication to gastric bypass (eg. celiac sprue, pancreatic insufficiency)
- A severe concurrent illness that is likely to limit life or require extensive systemic treatment (e.g. cancer)
- A pre-existing major complication of diabetes:
- unstable, proliferative retinopathy
- severe autonomic cardiac neuropathy or intestinal neuropathy
- Myocardial infarction within the previous year, current unstable angina, or poorly-controlled congestive heart failure (Stage III)
Exclusion
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00999050
Start Date
October 1 2009
End Date
November 1 2013
Last Update
January 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medical College New York Prysbyterian Hosptial
New York, New York, United States, 10065